Navigation Links
Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an agreement with Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow System and VerifyNowTests for use in clinical trials.

The VerifyNow System is widely used by practicing physicians to assess patients' platelet response to various antiplatelet therapies already available on the market, such as aspirin, P2Y12 inhibitors (e.g. Plavix® and Effient®)and GP IIb/IIIa inhibitors. The VerifyNow System is also a frequently used tool of clinical researchers to measure the antiplatelet effect of drugs in development.  By incorporating the VerifyNow System in pharmaceutical clinical trials, data are generated to support the integration of platelet reactivity testing in the patient care pathway as new agents are introduced to the market.

"With the signing of this agreement, Accumetrics is solidifying its role as a premier partner of pharmaceutical companies in the development and validation of new and emerging antiplatelet drugs," said Timothy I. Still, President and CEO of Accumetrics.  "With the trend towards individualized and targeted approaches to treating patients, the VerifyNow System plays an important role at both the commercial and development ends of the spectrum."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company. CONTACT: Megan RusnackLippert/Heilshorn & Associates212-838-3777mrusnack@lhai.comTimothy I. StillPresident and CEOAccumetrics858-404-8260press@accumetrics.com
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics Closes 2010 With Positive Outlook
2. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
3. Accumetrics Closes 2009 with Positive Outlook
4. Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Accumetrics Announces $16.5M in New Capital Financing
6. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
7. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
8. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
9. Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
10. Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company
11. Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):